结核性硬化症治疗中的范式转变:Everolimus的有效性
Roberto Previtali1, Giorgia Prontera2, Enrico Alfei3
1Pediatric Neurology Unit, Buzzi Children's Hospital, Milan, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Pharmacological research
|August 7, 2023
概括
结核性硬化综合体 (TSC) 是一种由mTOR通路过度激活引起的遗传性疾病. 作为一种mTOR抑制剂的Everolimus通过向潜在的分子缺陷,有效地治疗TSC的表现.
科学领域:
- 遗传学和分子生物学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 结核性硬化综合体 (TSC) 是一种自体主导性疾病,其特征是细胞生长异常,导致多个器官的瘤.
- 这种疾病是由于哺乳动物的目标拉巴胺素 (mTOR) 途径,特别是mTOR复合体1 (mTORC1) 的失调引起的.
- 目前对TSC的治疗方法在很大程度上是症状性的,并没有解决根源的分子原因,限制了它们的长期疗效.
结论:
- 埃弗罗利莫斯代表了结核性硬化综合体的向治疗策略,解决了潜在的mTORC1通路异常.
- 它能够纠正分子缺陷的能力比传统的症状治疗提供了显著的优势.
- 埃弗罗利斯有望改善TSC患者的长期治疗结果,TSC会影响大脑和心脏等器官.
更多相关视频
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
7.2K
08:38Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
17.0K
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K